galactosamine has been researched along with Hypertriglyceridemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartlett, VJ; Baum, SJ; Figueroa, AL; Gaudet, D; Geary, RS; Hurh, E; Karwatowska-Prokopczuk, E; Kingsbury, J; O'Dea, LSL; Piscitelli, P; Singleton, W; Tsimikas, S; Witztum, JL | 1 |
| Landmesser, U; Lüscher, TF | 1 |
1 trial(s) available for galactosamine and Hypertriglyceridemia
| Article | Year |
|---|---|
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Diabetes Mellitus, Type 2; Double-Blind Method; Galactosamine; Humans; Hypertriglyceridemia; Lipoproteins; Pharmaceutical Preparations; RNA, Messenger; Triglycerides | 2020 |
1 other study(ies) available for galactosamine and Hypertriglyceridemia
| Article | Year |
|---|---|
Advancing RNA-targeted therapy for personalised prevention of coronary disease: focus on ANGPLT3.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Coronary Disease; Diabetes Mellitus; Galactosamine; Humans; Hypertriglyceridemia; Lipoproteins; Pharmaceutical Preparations; RNA; RNA, Messenger; Triglycerides | 2020 |